Full Press Release Details
Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement.
KYMR
Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
Key Takeaway: Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
4.3%
average across 7 past catalysts
Cash runway
~83 mo
Minimal dilution risk
Lead asset
KT-621
Phase 2 · Atopic Dermatitis